ChromaDex (NASDAQ:CDXC) Rating Lowered to Buy at StockNews.com

ChromaDex (NASDAQ:CDXC) was downgraded by research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research report issued on Friday.

Several other equities analysts also recently commented on CDXC. HC Wainwright upped their price target on shares of ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Monday, November 4th. Roth Mkm boosted their price objective on shares of ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a report on Wednesday, November 6th.

ChromaDex Stock Up 0.5 %

CDXC stock opened at $5.51 on Friday. ChromaDex has a twelve month low of $1.36 and a twelve month high of $7.97. The company has a market cap of $420.87 million, a price-to-earnings ratio of 551.55 and a beta of 2.21. The business has a 50 day moving average price of $6.29 and a two-hundred day moving average price of $4.24.

ChromaDex (NASDAQ:CDXC) last released its earnings results on Thursday, October 31st. The company reported $0.02 earnings per share for the quarter. The business had revenue of $25.58 million during the quarter, compared to analysts’ expectations of $23.70 million. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%. During the same period last year, the business earned ($0.01) earnings per share. On average, equities research analysts anticipate that ChromaDex will post 0.04 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the business’s stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $6.19, for a total value of $230,026.59. Following the completion of the sale, the director now directly owns 244,179 shares of the company’s stock, valued at $1,511,468.01. The trade was a 13.21 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 9.64% of the company’s stock.

Institutional Investors Weigh In On ChromaDex

Institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC raised its holdings in shares of ChromaDex by 1.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,149,592 shares of the company’s stock worth $4,197,000 after purchasing an additional 17,963 shares during the period. State Street Corp boosted its position in ChromaDex by 11.3% during the third quarter. State Street Corp now owns 618,028 shares of the company’s stock worth $2,256,000 after purchasing an additional 62,692 shares during the period. Renaissance Technologies LLC boosted its position in ChromaDex by 8.4% during the second quarter. Renaissance Technologies LLC now owns 416,100 shares of the company’s stock worth $1,136,000 after purchasing an additional 32,400 shares during the period. JPMorgan Chase & Co. increased its stake in shares of ChromaDex by 11.1% in the third quarter. JPMorgan Chase & Co. now owns 331,916 shares of the company’s stock worth $1,211,000 after purchasing an additional 33,150 shares in the last quarter. Finally, WINTON GROUP Ltd bought a new stake in shares of ChromaDex in the second quarter valued at approximately $597,000. Institutional investors own 15.41% of the company’s stock.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.